People with pulmonary hypertension (PH) who took dipyrone to help manage pain were at a significantly lower risk of assisted ventilation and hospitalization then patients not using this prescription painkiller, according to a large, real-world study. Animal work suggests that dipyrone lowers blood pressure in the pulmonary arteries, and a…
The development program of AER-901, Aerami Therapeutics’ inhaled formulation of imatinib, will include pulmonary hypertension associated with interstitial lung disease (PH-ILD). According to the company, data from a completed Phase 1 clinical trial support the progression of AER-901 into Phase 2 trials for pulmonary arterial hypertension (PAH)…
Treatment with C75, an inhibitor of an enzyme called fatty acid synthase (FAS), partially reversed disease processes in a mouse model of pulmonary arterial hypertension (PAH), a study reports. C75 benefits may be linked to changes in pathways involved in cell proliferation and inflammation, among other processes, “thus inhibition…
Pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) — two treatment approaches for chronic thromboembolic pulmonary hypertension (CTEPH) — significantly improved blood flow dynamics and functional capacity in patients given either procedure, a study from Norway reported. PEA was more effective at reducing pressure and resistance in the lungs’…
A peptide called apelin-17 may be used as a diagnostic biomarker for idiopathic pulmonary arterial hypertension (IPAH), according to the results of a new study. Apelin-17 levels were found to detect IPAH with an accuracy similar to NT-proBNP and GDF-15 — two established biomarkers for pulmonary hypertension (PH)…
Note: The headline of this article was updated Feb. 27, 2023, to better reflect that Veletri is considered a safe and effective therapy at the approved and recommended dosing levels. Treatment with Veletri (epoprostenol AS) infusion was generally well-tolerated and safe, but did not lead to clinical improvements for…
A new game-style app aims to help doctors and medical imaging technicians learn to better identify signs of pulmonary hypertension (PH) on an echocardiogram, an ultrasound image of the heart. Called EchoRight Pro and developed by Janssen, the free app is available from Apple’s App Store…
Sensydia has completed a development study to assess the effectiveness of its Cardiac Performance System (CPS) in identifying people at risk for pulmonary hypertension (PH) and heart failure. CPS is a handheld, noninvasive device powered by artificial intelligence that uses heart sound analysis to detect PH. The device’s…
Children with pulmonary hypertension (PH) may experience a wide range of side effects from medications being used off label, and such reactions may differ from those affecting adults, a survey study found. “Further research is needed to better understand the clinical implications of these side effects,” the researchers wrote,…
Treatment with swietenine — extracted from the seeds of Swietenia macrophylla, a tree commonly called mahogany — eased the remodeling of lung blood vessels in a mouse model of pulmonary hypertension (PH). Researchers in China found that swietenine worked against this disease hallmark by inhibiting the growth of smooth muscle cells…
The experimental therapy levosimendan has been awarded a U.S. patent covering its use for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to developer Tenax Therapeutics. The United States Patent and Trademark Office (USPTO) issued a notice of allowance to Tenax for a patent for…
Pulmonary arterial hypertension (PAH) is associated with high utilization of healthcare resources by patients and with productivity loss, starting years before diagnosis, according to a study in Sweden. “The economic and clinical burden associated with PAH suggests that strategies for earlier diagnosis and more effective treatments are warranted,” researchers…
Get regular updates to your inbox.